Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Anti-CD33 CART cells |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-CD33 CART cells | CD33CART|CART-33 TCR zeta:CD137 Cells | Anti-CD33 CART cells consist of a preparation of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD33 linked to 4-1BB (CD137) and CD3zeta signaling domains, which induces lysis of CD33-expressing tumor cells and reduces tumor burden (PMID: 25721896). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03971799 | Phase Ib/II | Cyclophosphamide + Fludarabine Anti-CD33 CART cells | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |